BSEBoard Meeting4d ago · 7 Aug 2026, 01:11 pm
Approved the Unaudited Standalone and Consolidated Financial Results for the quarter ended on 30th June, 2026, along with year-to-date figures for the period from 1st April, 2026, to 30th ....
Vivanza Biosciences Ltd · 530057
✦ AI SummaryResults
Vivanza Biosciences Ltd approved unaudited standalone and consolidated financial results for Q1 FY2026-27, along with year-to-date figures for the period from April 1, 2026, to June 30, 2026.
Analysis Scores
Earnings Impact8/10
Growth Catalyst5/10
Governance Concern2/10
Regulatory Risk1/10
Balance Sheet Risk6/10
Liquidity Impact9/10
Market Sentiment6/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Vivanza Biosciences Ltd - 530057 - Board Meeting Outcome for Outcome Of Board Meeting To Consider And Approve Unaudited Financial Results (Standalone And Consolidated) For Quarter Ended 30Th June 2026
Attachments (1)
📄pdf
Download →
d512dc69-502c-4a98-8e51-e473efa8a4ce.pdf
View document text
VIVANZA BIOSCIENCES LIMITED
Regd. Office: 403, Sarthik 2, Opp. Rajpath Club, S. G. Highway, Ahmedabad 380054.
Phone: 079-26870953, email: info@vivanzabiosciences.com, website: www.vivanzabiosciences.com
CIN: L24105GJ1982PLC005057
Date: 07th August, 2026
Corporate Relationship Department,
BSE Limited
Phiroze Jeejeebhoy Tower,
Dalal Street,
Mumbai — 400001
Maharashtra, India
BSE Scrip Code- 530057 ISIN: INE984E01035
Subject: Outcome of Board of Directors Meeting of Vivanza Biosciences Limited (“the Company”)
Dear Sir/Madam,
Pursuant to Regulations 30 and 33 of the Securities and Exchange Board of India (Listing Obligations
and Disclosure Requirements) Regulations, 2015 (‘Listing Regulations’), we wish to inform you that the
Board of Directors of the Company at its meeting held today, i.e. Friday, 07th August, 2026, at the
Registered Office of the Company, has inter alia considered and approved the following businesses:
1. Approved the Unaudited Standalone and Consolidated Financial Results for the quarter ended
on 30th June, 2026, together with the Limited Review Report (Annexure –A).
2. The Board took note of the disclosure of interest received from the Directors pursuant to Section
184 of the Companies Act, 2013 and the intimation of disqualification under Section 164 of the
Companies Act, 2013.
3. The Board took note of the declarations received from the Independent Directors confirming
that they meet the criteria of independence as prescribed under Section 149(7) of the
Companies Act, 2013 and Regulation 25(8) of the SEBI (Listing Obligations and Disclosure
Requirements) Regulations, 2015.
The meeting of Board of Directors of the Company commenced at 12:45 P.M. and concluded at 13:00
P.M.
You are requested to kindly take the same on record and acknowledge.
Thanking You.
For, Vivanza Biosciences Limited
JAYENDRA MEHTA
MANAGING DIRECTOR
DIN: 08210602
Encl: As above